Cooper Companies Inc (COO) Stock AnalysisCOOCooper Companies Inc

The Cooper Companies, Inc. is a medical device company. The Company's segments include CooperVision and CooperSurgical. The CooperVision segment is engaged in developing, manufacturing and marketing a broad range of products for contact lens wearers, featuring advanced materials and optics. Its daily disposable silicone hydrogel contact lens products include MyDay daily disposable, MyDay daily disposable toric, MyDay daily disposable multifocal, and MyDay Energys. The CooperSurgical segment provides a portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. Its brands include ALLY II UPS, Advincula Delineator, Apple-Hunt Secondary Cannula, Bakri Postpartum Balloon, California Cryobank, Carter-Thomason, Cell Care, Cells for Life, Coda, Cord Blood Registry, Core Cryolab, Donor Egg Bank USA, ER-Complete, Embryo Options, and Endosee. It operates in the Healthcare sector (OPHTHALMIC GOODS industry).

Currently, Cooper Companies Inc is trading at $54.37, which is below the average analyst price target of $73. This suggests potential upside. However, the RSI is at 27.192, indicating the stock is oversold, which could lead to a price rebound. The company has shown a significant net income increase to $432.8 million in Q3 2026, but it also reported a net loss of $77.9 million in Q2 2026, indicating volatility. The main risk is the forecasted revenue growth of only 0% to 2% for Q4 2026, which could limit short-term price appreciation.

15 analysts cover COO: 10 rate it Buy, 5 Hold and 0 Sell. The average price target is 90.33.